Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Charles Williamson

Ophthalmology Milledgeville, GA Medical Doctor

NPI 1699737205 CMS profile 349113

111 Fieldstone Dr, Suite 100, Milledgeville, GA 31061

Open in the dashboard

General payments

$1,414

87 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Charles Williamson of Milledgeville, GA is reported in the CMS Open Payments database as having received $1,414 across 87 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $463 29
2021 General $464 30
2020 General $276 15
2019 General $212 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Williamson
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Charles Williamson were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Charles Williamson Ophthalmology median Middle half National median
2019 $212 $258 $104–$655 $163
2020 $276 $126 $45–$321 $114
2021 $464 $205 $76–$534 $132
2022 $463 $266 $100–$678 $149
2023 $0 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Sun Pharmaceutical Industries Inc. $465 26 payments
  2. Novartis Pharmaceuticals Corporation $310 20 payments
  3. Allergan Inc. $284 20 payments
  4. Kala Pharmaceuticals, Inc. $142 8 payments
  5. AbbVie, Inc. $104 6 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $29 2 payments
  7. TissueTech, Inc. $29 2 payments
  8. Shire North American Group Inc $21 1 payment
  9. Alcon Vision LLC $17 1 payment
  10. Oyster Point Pharma, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,414 87 payments
Products named General payments · program years 2019–2022
  1. Cequa $402 23 payments
  2. Xelpros $398 21 payments
  3. BromSite $320 18 payments
  4. XIIDRA $296 19 payments
  5. INVELTYS $142 8 payments
  6. VUITY $138 8 payments
  7. LUMIGAN Ophthalmology $119 8 payments
  8. LUMIGAN Ophthalmology $113 8 payments
  9. EYSUVIS $60 4 payments
  10. RESTASIS MULTIDOSE $39 3 payments
  11. Other $210 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Ophthalmology: 891

Drug cost

$1,081

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Travoprost Generic 15 $1,081

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record